Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Short Interest Down 82.0% in July

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) saw a significant decrease in short interest during the month of July. As of July 15th, there was short interest totaling 3,865 shares, a decrease of 82.0% from the June 30th total of 21,436 shares. Approximately 3.0% of the shares of the company are short sold. Based on an average daily volume of 2,327 shares, the days-to-cover ratio is presently 1.7 days.

Bitwise MARA Option Income Strategy ETF Stock Performance

Shares of Bitwise MARA Option Income Strategy ETF stock remained flat at $14.52 during trading on Monday. 1,319 shares of the stock traded hands, compared to its average volume of 4,887. Bitwise MARA Option Income Strategy ETF has a fifty-two week low of $11.99 and a fifty-two week high of $43.70. The company has a 50 day moving average of $16.60 and a two-hundred day moving average of $15.50. The stock has a market cap of $1.89 million, a PE ratio of 290.40 and a beta of 2.74.

Insider Buying and Selling

In related news, insider Helen Louise Collins sold 5,000 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total transaction of $219,000.00. Following the completion of the transaction, the insider directly owned 25,000 shares in the company, valued at $1,095,000. This represents a 16.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Orbimed Advisors Llc sold 860,123 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $45.36, for a total value of $39,015,179.28. Following the completion of the sale, the insider directly owned 219,405 shares in the company, valued at $9,952,210.80. This represents a 79.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,172,549 shares of company stock valued at $53,017,056 over the last quarter. Company insiders own 37.30% of the company’s stock.

About Bitwise MARA Option Income Strategy ETF

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.